Arcutis Biotherapeutics announced the U.S. Food and Drug Administration has accepted for review the company’s new drug application for roflumilast foam 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older. The application was assigned a Prescription Drug User Fee Act target action date of December 16, 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARQT:
- Arcutis to Present at Upcoming Investor Conference
- Arcutis Biotherapeutics price target lowered to $47 from $50 at Morgan Stanley
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
- Arcutis Biotherapeutics announces new coverage for ZORYVE cream 0.3%
